Note: Descriptions are shown in the official language in which they were submitted.
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- -
"METHOD AND DEVICE FOR NON-INVASIVE PRENATAL DIAGNOSIS"
Technical field
The present invention concerns methods for non-invasive
prenatal diagnosis, in particular for the identification of
genetic and chromosomic disorders in the foetus.
State of the art
Prenatal diagnosis for chromosomic disorders was introduced
with the aim of highlighting abnormalities of the chromosomes
in the foetus.
So far, the diagnostic certainty of a foetus being affected by
a chromosome disorder can be obtained only by means of
invasive diagnostic tests, examining the embryonic cells in
order to determine the karyotype by means of amniocentesis,
sampling of the chorionic villi or cordocentesis.
All these tests are invasive and involve an increased risk of
miscarriage. They are therefore usually recommended for women
over the age of 35, or women who in a previous pregnancy have
had a child affected by chromosome disorders or when
ultrasound scanning identifies a foetus with a malformation.
The discovery of the existence of foetal cells, although rare,
in the maternal circulation has led many
groups to research
and develop methods for the isolation and recovery of said
cells which permit non-invasive prenatal diagnosis. In
particular, there are three main types of foetal cells able to
pass through the placental barrier: lymphocytes, trophoblasts
and erythroblasts. Of these, research has been directed above
all at studying methods for the isolation of
foetal
erythroblasts
from the peripheral maternal blood and
trophoblasts, epithelial cells deriving from the placenta.
Isolation of the trophoblasts from the peripheral blood is
limited by their multinucleate morphology, whereas it has been
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 2 -
demonstrated [8-13] that these cells are present, between the
6th and 15th week of gestation, in transcervical samples. It
should be noted that the trophoblasts which migrate from the
placenta often adhere to other trophoblasts or maternal cells
forming clumps.
The identification of foetal cells has also recently been made
possible by molecular biology methods applied directly to non-
cultivated foetal cells. Said methods are for example prenatal
FISH (Fluorescent In Situ Hybridization) and Quantitative
Fluorescent-Polymerase Chain Reaction (QF-PCR). QF-PCR is a
method able to identify and simultaneously quantify
chromosome-specific DNA sequences which, being applicable to
individual cells, has permitted genetic analysis on the basis
of a very low number of foetal cells. In literature there are
numerous publications including some reviews [1-6, see
References at the end of the description], the content of
which is incorporated here for the parts necessary for simple
reference, concerning the use of QF-PCR in prenatal analyses.
D.W. Bianchi and colleagues developed [14-27] a system of
isolation of the foetal nucleated erythrocytes (NRBCs) from
maternal blood based on multiparametric scoring; the
parameters include two morphological characteristics
(roundness and morphology of the nucleus) and two properties
of the foetal haemoglobin marking (fluorescence intensity and
peripheral luminosity of the cytoplasm).
The protocol
provides for separation of the mononucleated cells on density
gradient and enrichment by depletion of leukocytes (MACS with
antibodies for CD15 and CD45) and isolation on cytofluorimeter
with FACS method using a gamma anti-haemoglobin antibody. The
cells identified via the multiparametric scoring are recovered
using a micromanipulator under microscopic observation.
The scoring system is very laborious and use of the
micromanipulator causes the loss of part of the cells. In
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 3 -
general this method has shown a 74% sensitivity in the
recovery of foetal cells combined with a frequency of false
positives of 56.
Separation of the mononucleated cells on density gradient and
enrichment of the sample by MACS with depletion of CD71+
cells, further marked with specific antibodies for the gamma
and epsilon foetal haemoglobin chains, is also known from
other works [7]. Said marking can, however, produce
aspecifics, as there are cases of production of foetal
haemoglobin in adult cells, or due to the cross-link between
the antibody for the foetal haemoglobin and the adult
haemoglobin, caused by the similarity of these haemoglobin
chains.
MonaLiza Medical Ltd. (US patent 2005/0181429 Al) developed a
prenatal genetic analysis method using transcervical cells.
The method is based on the use of a Pap smear cytobrush for
the recovery of transcervical samples, which are processed by
means of cytocentrifugation for the preparation of slides.
The transcervical cells are marked and analysed under the
microscope and their location and coordinates on the slide are
memorised. The slide is analysed in FISH and the trophoblastic
cells are identified using the coordinates obtained
previously. The disadvantage of said method is that during the
processing for preparation of the slide,
part of the
transcervical cells are lost, with a no-call due to lack of
trophoblasts.
AVIVA-Biosciences Corporation (see for example EP-A-1439897)
developed a system of enrichment based on biochips to isolate
foetal cells from maternal blood. This method uses a reagent
which permits removal of the majority of the erythrocytes,
sorting by means of highly specific magnetic beads and a
cocktail of specific antibodies for foetal antigens and
enrichment by means of high resolution filtering chambers with
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 4 -
pores having variable diameter according to the type of cells
to be isolated.
Said method, however, is confined to the selection of foetal
cells by means of enrichment of the sample, which does not
limit the possibility of having contaminating maternal cells
and therefore the consequent risk of an unreliable genetic
analysis.
In short, none of the above-mentioned non-invasive methods has
so far demonstrated that it can be used as a routine practice
for the diagnosis of foetal aneuploidies and/or other
chromosome defects.
The aim of the present invention is therefore to provide a
method for non-invasive prenatal diagnosis, based on the
sampling of an organic maternal fluid, with high probability
of containing circulating foetal nucleated cells and their
subsequent isolation, in particular a uterine, endocervical or
transcervical fluid, or peripheral maternal blood. A further
aim of the present invention is to provide a method for
prenatal diagnosis that can be automated, without false
negatives, and with a low number of false positives and no-
calls.
Summary of the invention
The present invention concerns methods and devices for non-
invasive prenatal diagnosis, in particular for the
identification of genetic abnormalities in the foetus.
According to the present invention, therefore, the diagnosis
is performed on the basis of an organic maternal fluid with
high probability of containing foetal nucleated cells and the
subsequent isolation thereof, in particular from a uterine,
endocervical or transcervical fluid or peripheral maternal
blood, identifying and analysing the foetal cells present in
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 5 -
it , proceeding according to the method of claim 1.
According to the present invention, the uterine, endocervical
or transcervical fluid or the peripheral maternal blood is
firstly processed via one or more enrichment stages of the
foetal nucleated cells. The method is characterised by the use
of a microfluidic system able to individually select, in an
easily automatable and repeatable way, single cells from the
enriched sample. By means of a microfluidic system of
isolation of single cells, it is possible to obtain a set of
foetal cells with purity sufficient to perform a genetic
diagnosis.
By microfluidic device we mean a device suitable for managing
volumes of liquid with a laminar flow.
By microfluidic device we furthermore mean a device which has
at least one dimension smaller than 1 mm.
By device able to individually select single cells we mean a
device able to perform the selection of one or more single
cells, one at a time or simultaneously,
on the basis of
parameters assessed individually on each cell.
The genetic analysis can then be performed via techniques such
as Quantitative Fluorescent PCR (QF-PCR), if necessary using
analysis of the cells of the mother for the comparison, FISH,
karyotype or Comparative Genomic Hybridization (CGH).
The use of a microfluidic system offers various advantages
including the possibility of having disposable systems,
without risks of contamination between the different analyses
or the need for thorough washing of the equipment. Furthermore
the use of a microfluidic system offers the possibility of
having automatic or semiautomatic systems, characterised by a
high level of reliability.
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 6 -
Further characteristics and advantages of the invention will
appear clear from the following description of some non-
limiting implementation examples, with reference to the
figures of the accompanying drawings.
Brief description of the figures
Fig. 1 shows a summary diagram of the non-invasive prenatal
diagnosis method according to the present invention.
Fig. 2 shows an image of the chip with 10X magnification with
filter for fluorescence of the DAPI. Three nuclei can be seen,
corresponding to three single cells.
Fig. 3 shows an image of the chip with 10X magnification with
filter for fluorescence of the FITC. The area photographed is
the same as that of fig. 2 and two Hb-e positive cells and one
Hb-e negative cell can be seen.
Fig. 4 shows an electropherogram relative to analysis of the
chromosome marker AMXY, D21511 and HPRT. The upper plot refers
to the analysis performed on foetal cells recovered from
maternal blood, the lower plot refers to the analysis
performed on maternal cells. The graph shows the presence of
the sex chromosomes X and Y in the foetus and at D21511 the
foetal cells have a first allele inherited from the mother (M)
and a different second allele (of paternal origin (P)).
Fig. 5 shows an electropherogram relative to analysis of the
chromosome markers D185391, D135631 and D2151411. The upper
plot refers to the analysis performed on the foetal cells
recovered from maternal blood, the lower plot refers to the
analysis performed on maternal cells. The graph shows for the
markers D135631 and D2151411 the presence of two alleles
(normal heterozygote) and contamination by maternal cells can
be excluded.
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 7 -
F i g . 6 shows an electropherogram relative to analysis of the
marker D21S1437 and D21S1446. The upper plot refers to the
analysis performed on foetal cells recovered from maternal
blood, the lower plot refers to the analysis performed on
maternal cells. The graph shows the presence of two alleles
(normal heterozygote) and contamination by maternal cells can
be excluded.
Fig. 7 shows an electropherogram relative to analysis of the
marker D18S535. The upper plot refers to the analysis
performed on foetal cells recovered from maternal blood, the
lower plot refers to the analysis performed on maternal cells.
The graph shows the presence of two no-call alleles (normal
heterozygote).
Fig. 8 shows a flow chart of a preferred embodiment of the
method according to the present invention.
Fig. 9 shows the trend of the number of foetal cells in a
single cage (NCISCC) according to the mean density of cells
per cage (ACPC).
Fig. 10 shows schematically an example of a device for
implementation of the method (or of the substantial and
characterising part of it) according to the invention.
Detailed disclosure
The subject of the present invention is a method for
performing non-invasive prenatal diagnosis.
Collection of transcervical samples
The transcervical samples (TCC) can be taken from different
levels of the uterus (external bone, lower part of cervical
canal, lower uterine pole, intrauterine cavity) by means of
various techniques: aspiration of the cervical mucus,
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 8 -
cytobrush or swab, endocervical lavage and intrauterine lavage
(IUL).
Enrichment starting from peripheral blood
The proportion of foetal cells can be enriched using various
methods, for example centrifugation on density gradient,
consisting of solutions such as Ficoll or Percoll; mechanical
enrichment, based on microfabricated filters which select nRBC
and empty the sample of RBC; enrichment via dielectrophoretic
separation by means of a specific device, the
Dielectrophoretic activated cell sorter (DACS); selective
lysis, for example selective lysis of the erythrocytes of no
interest; immunomagnetic separation, by means of
immunomagnetic beads with positive selection (using beads
linked to specific antibodies for the foetal population to be
recovered) or negative selection (depletion of cellular
populations of no interest), and in which the two types of
selection can be coupled to increase the specificity of the
method (as, for example, in US2006/0051775 - Bianchi); FACS,
on cells marked with specific fluorescent antibody for foetal
antigens.
The majority of these methods are also automated and all the
separation methods can be preceded by separation of total
mononucleated cells by means of centrifugation on density
gradient or alternatively they can be applied on blood in
toto.
In general the process starts from a dilution, but it is not
strictly necessary for all the techniques.
Other enrichment techniques
A further technique well known to persons skilled in the art
is called MACS by Miltenyi Biotech, or Easy-sep by Stem-cell
technologies.
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 9 -
To summarise, considering the case of organic fluid consisting
of peripheral maternal blood, enrichment of the blood sample
in the population of cells comprising at least one type of
foetal cells can be obtained via a process in successive
phases with, for example, a first phase in which total
mononucleated cells are separated from the maternal sample,
previously diluted in PBS/EDTA by means of Ficoll density
gradient centrifugation. Obviously, as an alternative, any one
of the other methods summarised in figure 1 could be used, for
example enriching of the maternal sample via a selection of
cells made on the basis of at least one parameter chosen from
the group consisting of:
a. density;
b. morphology;
c. .. electrical properties;
d. chemical properties;
e. mechanical properties;
f. expression-of surface antigens;
g. expression of intra-cytoplasmatic antigens;
h. .. dielectric properties;
i. magnetic properties;
or combinations of the same.
Subsequently enrichment of the foetal cells is further
obtained by means of a second phase in which the positive or
negative selection of cells is made, for example expressing
the CD71, from the mononucleated cells recovered in the first
step. Obviously the second enrichment step can comprise a
selection made on the basis of at least one of the following
characteristics of the population of cells comprising at
least one type of foetal nucleated cells:
a. express the CD71 surface antigen (as already described
and which represents the preferred form of the invention);
b. express the CD34 surface antigen;
c. express the GPA surface antigen;
d. not express the CD14 surface antigen;
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 10 -
e. not express the CD15 surface antigen;
f. not express the CD45 surface antigen.
Furthermore said second phase of enriching the sample in the
population of cells comprising at least one type of cells can
be performed via one of the following techniques:
a. MACS or Magnetic Activated Cell Sorter;
b. DACS or Dielectrophoretic Activated Cell
Sorter;
c. FACS or Fluorescence Activated Cell Sorter.
Marking of the foetal cells
Immunostaining of trophoblasts
If the sample is a TCC sample, before marking, the sample is
incubated with acetyl-cysteine and agitated vigorously to
dissolve the clumps and obtain a suspension of single cells.
For identification of the foetal cells, a marking with a
specific antibody for the foetal cells (able to discriminate
them from the maternal ones) is used, proceeding as in the
known art. The trophoblasts can be marked using a variety of
antibodies directed against specific antigens:
HLA-G, NDOG-5, BC1, Factor XIII, FD0202N, JunD, Fra2, HASH2
and PP5 (placental protein), specific for the extravillous
trophoblasts;
FT1.41.1, 103, NDOG-1 and AB-154, specific for the syncytium
trophoblasts;
CK-7 (cytokeratin-7), CHL1 (CD146), CHL2, H315, HLA-C, aHCG,
IGF-II, PAI-1 and p57, expressed on the trophoblasts;
PLAP (placental alkaline phosphatase), AB-340 and D6,
expressed on syncytium trophoblasts and cytotrophoblasts;
Tapasin and CAR, specific for invasive or extravillous but not
villous trophoblasts;
PLAC1, PLAC4, PLAC8 and PLAC9, placental specifics, in
particular of the trophoblast lineage cells;
PAR-1 (protease activated receptor), expressed on placental
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 11 -
cells from the 7th to the 10th week of gestation;
GLUT-12 (glucose transporter protein), expressed on syncytium
trophoblasts and extravillous trophoblasts from the 10th to
the 12th week of gestation;
NDPK-A (nucleoside diphosphate kinase A), expressed on
extravillous trophoblasts during the first three months of
pregnancy.
Immunostaining of erythroblasts from samples of peripheral
maternal blood
For identification of the foetal cells, a marking with a
second specific antibody for the foetal cells (able to
discriminate them from the maternal ones) is used, different
from the antibody used for the enrichment which, as described
above, is not necessarily specific for the foetal cells.
In this case the following can be used:
= antibodies that recognise surface antigens (like i-
antigens);
= intra-cellular antigens (for example, the globin chains y
or e. In these cases the cells are preferably fixed and
permeabilised, as in the known art, to permit good marking.
It should be noted that although from previous studies use of
the anti-i-antigen antibody to mark foetal cells is known,
said antibody was used directly in a device based on density
gradient. Marking of the foetal cells by means of i-antigen
antibody preceded by enrichment of the CD71+ cells has the
advantage of performing a pre-selection of the foetal cells
(sample enriched in foetal erythroblasts) and facilitating
identification of the cells of interest, furthermore obtaining
a very sensitive and specific marking.
Cells already marked
The foetal cells can be already marked if an antibody which is
specific for the foetal cells (able to discriminate them from
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 12 -
the maternal ones) and is fluorescent or conjugated with a
fluorescent bead or conjugated with a fluorescent secondary or
tertiary antibody has been used in the enrichment. In this
case the enriched sample can be injected directly into the
microfluidic device able to select single cells, since it is
already possible to identify the foetal cells.
Isolation of single foetal cells
Subsequently, the sample containing the cells is placed in a
microfluidic device able to individually select single cells,
of any known type. For said purpose a dielectrophoretic
isolation can be used
(DEPArray, using for example the
techniques described in PCT/IB2007/000963 Or
in
PCT/IB2007/000751, or [31] and [321), or opto-electronic traps
or optophoretic isolation or laser tweezers [28-30]. The
content of said documents [28-30] and [31-32] is incorporated
here for the parts necessary for simple reference.
Identification of the cells of interest can be performed for
example by sensors:
- external
- optical such as a fluorescence microscope,
or also
internal
- optical, as illustrated in the patents PCT/IB2006/000636 and
W02007010367, which describe an integrated method of
identification of the fluorescent cells
impedentiometric, as illustrated in the patents
PCT/IB2006/000636 and W02007010367 to identify dielectric
beads associated with cells.
Genetic analysis
Various types of analysis can be performed on the foetal cells
recovered permitting genetic or chromosomic characterisation
at different levels of resolution and sensitivity and
according to the diagnostic purpose of the study.
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 13 -
In the event of supposed chromosome disorders, analysis of the
karyotype with classic or molecular method (FISH) or the study
of chromosome markers by means of QF-PCR can be performed. The
acquisition or loss of genetic material can also be
investigated by means of Comparative Genomic Hybridization.
Examples of preferential embodiments of the invention
By way of non-limiting example of the object of the invention,
a preferential embodiment of the method according to the
present invention is given, following the flow chart indicated
in Fig. 8.
Collection of sample
10 ml of peripheral blood are taken from a pregnant woman.
Enrichment
The preferred embodiment of the invention comprises a process
in successive phases having a first phase in which total
monoucleated cells are separated from the maternal sample.
Said phase comprises a 1:1 dilution of the maternal blood with
PBS pH 7.2. The sample diluted is then stratified on a single
Ficoll gradient 1.077 g/ml and centrifuged at a speed of 300 g
for 30 min at 22 C. The ring of cells that has accumulated
above the Ficoll is collected and transferred to a sterile
test tube.
According to a characteristic of the present invention, a part
of the blood or mononucleated cells is not further processed
and is used for analysis of the maternal DNA.
Enrichment of the foetal nucleated cells is then further
obtained via a second phase, in which cells expressing the
CD71 are positively selected from the mononucleated cells
recovered in the first step. The positive selection is
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 14 -
performed by means of immunomagnetic separation (MACS -
Miltenyi Biotec) with the use of anti-CD71 antibodies
conjugated with magnetic beads.
For the immunomagnetic separation, the cells are re-suspended
in 80 l of PBS every 107 cells and then 20 l of anti-CD71
micro-beads (Miltenyi Biotec) are added every 107 cells. After
an incubation of 15 min at 4 C, the cells are passed through a
column connected to a magnetic field which retains the
positive CD71 cells. The cells retained are then eluted from
the column and used for the subsequent phase.
Isolation
The CD71+ cells (positive for CD71) thus obtained are fixed
with formaldehyde 3.7% for 15 min at 22 C. The cells fixed are
then permeabilised with a solution of NP-40(Sigma Aldrich)
0.1% in PBS. An antibody (1 g/ml) which recognises the gamma
chain of the foetal hemoglobin conjugated with the
fluorochrome FITC is added to the permeabilised cells.
According to an important aspect of the invention, the sample
is furthermore, in combination, countermarked with DAPI (or
other suitable marker) to show the nuclei of all the cells.
Before being loaded in the chip for dielectrophoretic
manipulation and isolation of the foetal cells, the sample
undergoes a quality control to verify the fluorescence
intensity of the marking and the total cellular content. A
portion of the marked sample is re-suspended in a minimum
specific buffer volume useful for the dielectrophoretic
manipulation and is loaded in a device for quality control of
the sample and examined under the fluorescence microscope: the
fluorescence intensity of the cells is observed in the various
channels and a count is performed of the cells marked in DAPI
(total nucleated cells). If the cellular concentration is
above the optimal concentration for correct operation of the
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 15 -
device for isolation of the single cells, the sample is
diluted to obtain the required concentration; if the total
number of cells is too low to allow the recovery of a minimum
number of foetal cells, the foetal cells are not recovered
(no-call result).
For calculation of the optimal concentration of cells we refer
to a specific commercial device (DEPArraym", Silicon Biosystems
SpA), W00069565, based on mobile dielectrophoresis cages, in
particular the model CONV600k comprising 100,000 cages.
A preferential method of use of said device provides for the
following steps:
1. Select the cages containing a foetal cell (positive to
marking).
2. If the cell is part of a cluster, i.e. it shares the cage
with other non-foetal cells, divide the cells of the cluster
into separate cages until the foetal cell is isolated in a
cage not shared with other non-foetal cells.
If the foetal
cell does not separate from the other non-foetal cells,
discard it.
3. Recover all the foetal cells in one single cage.
A further alternative preferential method of use of said
device provides for the following steps:
1. Select the cages containing a foetal cell (positive to
the marking).
2. If the cell is part of a cluster, discard it from the
list of cells to be recovered.
3. Recover all the foetal cells in a single cage.
In this second case, the choice of the mean density of cells
per cage (ACPC) to be injected in the chip is made taking
account of the number of total cells present in the sample
(NCELLSTOT) and the expected percentage of foetal cells (PCI).
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 16 -
In fact, when the ACPC increases, the number of foetal cells
present in the manipulation chamber of the chip increases.
However, the probability of each cell belonging to a cage with
single cell decreases, and the number of foetal cells in a
single cage (NCISCC) therefore reaches a maximum for ACPC-=1.
Said value is independent of PCI, and can be defined a
normalised value of NCISCC with respect to the theoretical
maximum for ACPC=1, the trend of which is shown in the graph
of Fig. 9. Said concentration maximises the number of cells
that can be recovered at each flushing of sample into the
manipulation microchamber. This is a good choice if the total
number of foetal cells that can be recovered is sufficient for
the genetic analysis downstream.
As ACPC increases, there is a growing monotonic increase in
the percentage of cells to be discarded due to the fact that
they share the cage with other non-foetal cells, as
illustrated in Fig. 9 in reference to the normalised value
with respect to the number of foetal cells present in the
manipulation microchamber (normalized cell-waste).
If the number of recoverable cells is below the minimum
required for the analysis downstream, the sample can be
diluted and a greater number of flushings performed to recover
a greater number of foetal cells.
The optimal ACPC value to recover a sufficient number of
foetal cells with the lesser number of flushings can be
calculated on the basis of the statistical analysis determined
above, for example with calculations based on the expected
number of foetal cells and the minimum number of cells for the
genetic analysis, therefore identifying a minimum recovery
efficiency (ratio between cells in single cage/cells in cage
with other cells) of the foetal cells present in the sample.
From said efficiency a maximum value of ACPC can be deduced,
hence a minimum number of flushings to process the entire
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 17 -
sample with said recovery efficiency.
The sample is then loaded in a chip for the isolation of cells
by means of mobile dielectrophoresis cages (DEPArray'
W00069525, Silicon Biosystems SpA, for example as part of a
package or overall device like the one schematically
illustrated in figure 10) and undergoes scanning,
identification and selection, sorting and recovery of the
foetal cells. The caged cells are observed (scanning)
automatically or manually under a microscope with three
different fluorescence channels (or in three different
wavelengths): in the non-limiting case described here, the
blue channel allows verification of the presence of the
nucleus and if necessary its morphology (e.g. marking with
DAPI) and the green channel highlights the cells that have
been marked with the specific foetal antibody which is
conjugated with a fluorophore emitting in the green wavelength
(e.g. FITC). According to one aspect of the invention, a third
channel is also used, different from the first two (e.g. the
channel emitting in the red wavelength, as for the filter used
to detect the fluorescence of the TRITC), and for which no
fluorescent marker has been used; this permits identification
of the autofluorescent cells, for which any signal detected in
the DAPI and green channels would not be specific.
Alternatively the third channel can be used to highlight cells
conjugated with an antibody linked to a fluorophore, like for
example the CD45, to identify the cells to be discarded.
The selection of cells is therefore made by selecting the
cages that contain one single nucleated cell (positive to the
DAPI, Fig. 2), which have a strong specific foetal antibody
signal (positive to the FITC/Alexa, Fig. 3), and which have
low or nil autofluorescence, detected on other channels (e.g.
red channel).
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 18 -
To further improve the selectivity of the method, the
fluorescent markers, in particular the foetal marker, instead
of consisting of simple fluorescent molecules, can consist of
fluorescent beads conjugated with antibody able to recognise
the cells of interest, in this case the foetal cells.
The cells are recovered in a few microlitres (< 40
microlitres) in a 0.2 millilitre PCR tube.
Genetic analysis
From said cells thus obtained the DNA is extracted which is
amplified and analysed for the presence of chromosomic
aneuploidies, preferably operating in the same microfluidic
device as the one used for the selection and, if necessary,
already used previously for at least part of the enrichment
process (for example in the case of use of the DACS
technology); in this case the device can resemble the one
illustrated in figure 10.
The equipment contains an array of electrodes as in the known
art, but is characterised by a main microchamber (CHM) and a
plurality of secondary microchambers (CHJ), all delimited on
at least one face by one single chip or by a plurality of
separate chips, bearing an array of electrodes that can be
activated. The main microchamber can be filled with a sample
comprising at least one cell via the relative inlets (IM1) and
outlets (0M1). Each secondary microchamber (CHJ) is preferably
of substantially greater dimensions but comparable to those of
a cell. Preferably each secondary microchamber is connected to
the main microchamber via a configuration channel (length
and/or form) sufficient to forestall (prevent or at least
limit) dispersion of the sample by diffusion and contamination
towards other microchambers, in the time necessary for the
analysis. According to the example illustrated, there is a
plurality of secondary microchambers for the lysis connected
to a channel for the capillary electrophoresis on chip, for
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 19 -
example with cross joint. Alternatively a series of channels
can be provided for the capillary electrophoresis with double
T junction, according to the known art.
Optionally, at the
end of the channel for the capillary electrophoresis, there is
an integrated sensor, of the impedentiometric and/or optical
type, able to produce an electropherogram based on the
migration time of the compounds analysed from the intersection
(cross or double T) to the sensor itself. According to figure
10, in particular, each microchamber of the plurality of
microchambers is connected to a capillary for the
electrophoresis (CAPJ) via a fluidic outlet (0J) of each
secondary microchamber.
Extraction of the DNA of the recovered foetal cells is
performed by alkaline thermolysis.
The determination of chromosome alterations is performed via
analysis of the STR (Short Tandem Repeat) or microsatellites
by means of QF-PCR. The technology of fluorescence capillary
electrophoresis permits the simultaneous analysis of several
STRs via the appropriate choice of fragments of DNA marked
with different fluorescent molecules.
At least three different STRs, with high heterozygosis
frequency in the population, of each of the chromosomes 13, 18
and 21 and three markers of the sex chromosomes are amplified
in multiplex-PCR. In the case of a no-call, for example due to
the presence of STR in homozygosis, a further STR of the same
chromosome is amplified. The STRs analysed are:
D21S11,
D21S1410, D21S1411, D21S1412, D21S1435 and D2151446 for
analysis of the chromosome 21; D13S631, D13S634, D13S258,
D13S305 and D13S742 for the chromosome 13; D18S535, D18S386,
D18S391, D18S858 and D18S51 for the chromosome 18; for
analysis of the sex chromosomes the markers AMXY and SRY, and
the STR X22, DXYS218, DXS6803, DXS6809, DXS8377, HPRT and SBMA
are analysed.
CA 02686338 2009-11-04
WO 2008/135837 PCT/IB2008/001083
- 20 -
Parallel to amplification of the DNA of the foetal cells, the
maternal DNA is analysed to recognise, according to one aspect
of the invention, the presence of possible maternal
contamination of the foetal cells or a possible external
contamination of the QF-PCR (Fig. 4-7).
In the electropherograms, obtained from the capillary
electrophoresis of the product of PCR with the automatic
sequencer (for example with ABI prism 310), the areas and the
dimensions of the peaks corresponding to the various alleles
of the amplified microsatellites are analysed. Simultaneous
analysis of the maternal DNA
can help as a control to
interpret the result of the genetic analysis, helping to
identify possible cases of laboratory contaminations and
contamination of the recovered foetal cells with maternal
cells.
The genetic analysis phase can also be performed, according to
a possible variation of the invention, by means of karyotype,
in which case the phase of enrichment of at least one
population of cells comprising at least one type of foetal
nucleated cells furthermore comprises the phases of:
I. blocking the cells in metaphase.
After stopping the cells in metaphase, fixing and
permeabilisation are performed for identification of the
foetal cells by means of an intra-cytoplasmatic antibody.
References
[1] van Zwieten MC, Willems DL, Litjens LL, Schuring-Blom HG,
Leschot N. How unexpected are unexpected findings in prenatal
cytogenetic diagnosis? A
literature review. Eur J Obstet
Gynecol Reprod Biol. 2005 May 1;120(1):15-21. Review.
[2] Nicolini U, Lalatta F, Natacci F, Curcio C, Bui TH. The
introduction of QF-PCR in prenatal diagnosis of foetal
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 21 -
aneuploidies : time for reconsideration. Hum Reprod Update.
2004 Nov-Dec;10(6):541-8. Review.
[3] Leung WC, Lau ET, Lao TT, Tang MH. Rapid aneuploidy
screening (FISH or QF-PCR): the changing scene in prenatal
diagnosis? Expert Rev Mol Diagn. 2004 May;4(3):333-7. Review.
[4] Hulten MA, Dhanjal S, Pertl B. Rapid and simple prenatal
diagnosis of common chromosome disorders: advantages and
disadvantages of the molecular methods FISH and QF-PCR.
Reproduction. 2003 Sep;126(3):279-97. Review.
[5] Adinolfi M, Pertl B, Sherlock J. Rapid detection of
aneuploidies by microsatellite and the quantitative
fluorescent polymerase chain reaction.
Prenat Diagn. 1997 Dec;17(13):1299-311. Review.
[6] Adinolfi M, Sherlock J. First trimester prenatal
diagnosis using transcervical cells: an evaluation. Hum Reprod
Update. 1997 Jul-Aug;3(4):383-92. Review
[7] Bianchi DW, Simpson JL, Jackson LG, Elias S, Holzgreve W,
Evans MI, Dukes KA, Sullivan LM, Klinger KW, Bischoff FZ, Hahn
S, Johnson KL, Lewis D, Wapner RJ, de la Cruz F. Foetal gender
and aneuploidy detection using foetal cells in maternal blood:
analysis of NIFTY I data. National Institute of Child Health
and Development Foetal Cell Isolation Study. Prenat Diagn.
2002 Jul;22(7):609-15.
[8] Shettles, LB (1971) Use of the Y chromosome in prenatal
sex determination. Nature, 230, 52.
[9] Adinolfi, M, Davies, A, Sharif, S et al. (1993) Detection
of trisomy 18 and Y-derived sequrnces in foetal nucleated
cells obtained by transcervical flushing, Lancet, 342, 403-
404.
[10] Adinolfi, M and Sherlock, J (1997) First trimester
prenatal diagnosis using transcervical cells: an evaluation,
Human Reproduction Update, 3 (4), 383-392.
[11] Miller, D, Briggs, J, S.Rahman, M, et al. (1999)
Transcervical recovery of foetal cells from the lower uterine
pole: reliability of recovery
and
histological/immunocytochemical analysis of recovered cell
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 22 -
populations, Human Reproduction, 14 (2), 521-531
[12] Bussani, C, Cioni, R, Scarselli B, et al. (2002)
Strategies for the isolation and detection of foetal cells in
transcervical samples, Prenatal Diagnosis, 22, 1098-1101.
[13] Bussani,- C, Scarselli, B, Cioni, R, et al. Use of the
quantitative fluorescent-PCR assay in the study of foetal DNA
from micromanipulated transcervical samples, Mol Diagn, 8 (4),
259-263
[14] Wang JY, Zhen DK, Falco VM, Farina A, Zheng YL, Delli-
Bovi LC, Bianchi DW. Foetal nucleated erythrocyte recovery:
fluorescence activated cell sorting-based positive selection
using anti-gamma globin versus magnetic activated cell sorting
using anti-CD45 depletion and anti-gamma globin positive
selection. Cytometry. 2000 Mar 1;39(3):224-30.
[15] Samura 0, Sekizawa A, Zhen DK, Falco VM, Bianchi DW.
Comparison of foetal cell recovery from maternal blood using a
high density gradient for the initial separation step: 1.090
versus 1.119 g/ml. Prenat Diagn. 2000 Apr;20(4):281-6.
[16] Sekizawa A, Farina A, Zhen DK, Wang JY, Falco VM, Elmes
S, Bianchi DW. Improvement of foetal cell recovery from
maternal blood: suitable density gradient for FACS separation.
Foetal Diagn Ther. 1999 Ju1-Aug;14(4):229-33.
[17] Sekizawa A, Samura 0, Zhen DK, Falco V, Bianchi DW.
Foetal cell recycling: diagnosis of gender and RhD genotype in
the same foetal cell retrieved from maternal blood. Am J
Obstet Gynecol. 1999 Nov;181(5 Pt 1):1237-42.
[18] Zheng YL, Zhen DK, DeMaria MA, Berry SM, Wapner RJ, Evans
MI, Copeland D, Williams JM, Bianchi DW. Search for the
optimal foetal cell antibody: results of immunophenotyping
studies using flow cytometry. Hum Genet. 1997 Ju1;100(1):35-
42.
[19] Geifman-Holtzman 0, Bernstein IM, Berry SM, Holtzman EJ,
Vadnais TJ, DeMaria MA, Bianchi DW. Foetal Rh]) genotyping in
foetal cells flow sorted from maternal blood. Am J Obstet
Gynecol. 1996 Mar;174(3):818-22.
[20] Bianchi DW, Klinger KW, Vadnais TJ, Demaria MA, Shuber
CA 02686338 2009-11-04
WO 2008/135837
PCT/IB2008/001083
- 23 -
AP, Skoletsky J, Midura P, Diriso M, Pelletier C, Genova M,
Erikson MS, Williams JM. Development of a model system to
compare cell separation methods for the isolation of foetal
cells from maternal blood. Prenat Diagn. 1996 Apr;16(4):289-
98.
[21] DeMaria MA, Zheng YL, Zhen D, Weinschenk NM, Vadnais TJ,
Bianchi DW. Improved foetal nucleated erythrocyte sorting
purity using intracellular antifoetal hemoglobin and Hoechst
33342. Cytometry. 1996 Sep 1;25(1):37-45.
[22] Zheng YL, Craigo SD, Price CM, Bianchi DW. Demonstration
of spontaneously dividing male foetal cells in maternal blood
by negative magnetic cell sorting and fish. Prenat Diagn. 1995
Jun;15(6):573-8.
[23] Zheng YL, Demaria M, Zhen D, Vadnais TJ, Bianchi DW. Flow
sorting of foetal erythroblasts using intracytoplasmic anti-
foetal haemoglobin: preliminary observations on maternal
samples. Prenat Diagn. 1995 Oct;15(10):897-905.
[24] Bianchi DW, Yih MC, Zickwolf GK, Flint AF. Transferrin
receptor (CD71) expression on circulating mononuclear cells
during pregnancy. Am J Obstet Gynecol. 1994 Jan;170(1 Pt
1):202-6.
[25] Bianchi DW, Shuber AP, DeMaria MA, Fougner AC, Klinger
KW. Foetal cells in maternal blood: determination of purity
and yield by quantitative polymerase chain reaction. Am J
Obstet Gynecol. 1994 Oct;171(4):922-6.
[26] Bianchi DW, Mahr A, Zickwolf GK, Houseal TW, Flint AF,
Klinger KW. Detection of foetal cells with 47,XY,+21 karyotype
in maternal peripheral blood. Hum Genet. 1992 Dec;90(4):368-
70.
[27] Bianchi DW, Stewart JE, Garber MF, Lucotte G, Flint AF.
Possible effect of gestational age on the detection of foetal
nucleated erythrocytes in maternal blood. Prenat Diagn. 1991
Aug;11(8):523-8.
[28] Reichle C, Sparbier K, Muller T, Schnelle T, Walden P and
Fuhr G, Electrophoresis, 2001; 22:272-82.
[29] Fiedler S, Shirley SG, Schnelle T and Fuhr G, Anal. Chem.
CA 02686338 2009-11-04
WO 2008/135837 PCT/IB2008/001083
- 24 -
1998; 70:1909-15.
[30] Enger J, Goksor M, Ramser K, Hagberg P and Hantstorp D,
Lab Chip, 2004; 4:196-200.
[31] Manaresi N, Romani A, Medoro G, Altomare L, Leonardi A,
Tartagni M and Guerrieri R, IEEE J. Solid-State Circuits,
2003; 38:2297-2305.
[32] Romani A, Manaresi N, Marzocchi L, Medoro G, Leonardi A,
Altomare L, Tartagni M and Guerrieri R, Proceedings of the
International Solid State Circuit Conference, 2004; 1:224-225.
